Founded in October 2019, Angels for Change is a global volunteer supported non-profit organization dedicated to Ensuring Access to Life Saving Drugs. Their mission is to end drug shortages through advocacy, awareness, and a resilient supply chain.  

Since their founding Laura has advocated on behalf of patients on hold from treatment because of a lifesaving drug shortage and worked within the supply chain to build drug shortage awareness, proactive solutions, and resolve patient and hospital level shortages. 

Laura has worked as an Adjunct Business Professor at Hillsborough Community College in Tampa Florida from 2004 - 2023. Prior to Academia, Laura worked in Marketing Strategy and Small Business Consulting. She graduated from University of Florida with a BSBA and from University of South Florida with a MBA. She lives in Tampa, Florida with her husband, Mike, and their three children Shelby, Abby and Cooper.

Allan Coukell, BSc(Pharmacy), is Chief Government Affairs & Public Policy Officer with Civica, Inc. (Civica Rx), a non-profit generic drug company created by U.S. health systems to mitigate and prevent drug shortages. He also leads policy for CivicaScript, the Civica operating unit created to bring down pharmacy drug costs for consumers. He previously served as Senior Director, Health Programs, at The Pew Charitable Trusts.  Coukell started his career as a clinical pharmacist in oncology and also spent many years as a health and science journalist. He is a board member of the End Drug Shortages Alliance, the Alliance for Building Better Medicine, and a prior board member of the Reagan-Udall Foundation for the FDA and the Medical Device Innovation Consortium. He is a graduate of the University of Manitoba and completed his hospital pharmacy residency at the Winnipeg Health Sciences Centre.

Meera Bhavsar is the U.S. Commercial lead in Pfizer’s Global Hospital & Biosimilars organization and has accountability for generic injectables, surgical, and biosimilars products. 

Meera has a deep breadth of experience in the pharmaceutical industry, having spent 29 years in both US and global roles spanning manufacturing, commercial development, and marketing. 

 After spending over three years at Merck’s West Point manufacturing site, Meera joined Pfizer in 2000, where she held roles of increasing responsibility within the Global Supply organization before transitioning in 2011 to the established products Commercial organization. Achievements include the US launch of 25 generic injectables, significantly increasing multi-source and differentiated drug delivery pipeline program value, managing the anesthesia portfolio through the COVID-19 pandemic, and crisis management and leadership during the tornado impact at the Rocky Mount manufacturing site.

 Meera received her B.S. in Pharmacy from Rutgers University, College of Pharmacy, and her M.B.A. from Stevens Institute of Technology. Meera and her husband, Karteek, live in New Jersey and have two grown children, Dilan and Jasmine, of whom she is very proud. In her free time, she loves to see the world with family and friends, scuba dive, and ski.

Anthony “Tony” Lakavage, EVP, Global External Affairs; Secretary, Board of Trustees and USP Convention, joined USP in 2015 when he launched the Global External Affairs division which includes Global Communications, US Government and Regulatory Affairs, International Government and Regulatory Affairs, and the USP Convention and Global Stakeholder Engagement. In 2018, his responsibilities expanded to include Secretary, USP Convention and Secretary, USP Board of Trustees. He is an officer of the USP Convention.

As leader of Global External Affairs, Tony leads our work to engage and influence public and regulatory policy – working with regulators, industry associations, and patient and practitioner groups to leverage USP standards to bring more quality medicines to more people everywhere. As Convention Secretary, Tony envisioned and implemented a new model of engagement across the 500 organizations in the USP Convention to foster more dialogue and advocacy across Convention sectors and international regional chapters. In addition, he oversees Convention governance including the development and adoption of the Resolutions that guide USP’s work. 

Tony’s experience includes leadership roles in public, regulatory and payment policy; government relations; social investing; corporate social responsibility; and communications. He has worked at the federal and state level in the U.S. and worked in Europe and the United Kingdom in international roles. He has been a longtime champion of LGBTQ+ diversity and inclusion throughout his career.

Dr. Nicolette Louissaint serves as the Chief Policy Officer for the Healthcare Distribution Alliance. In this role, she leads the organization’s work to build policy solutions that reinforce the role of pharmaceutical distributors in the healthcare ecosystem. 

She previously served as the executive director and president of Healthcare Ready, a 501(c)(3) organization focused on strengthening the healthcare supply chain before, during, and after disasters and disease outbreaks. Prior to this, Nicolette served as the Senior Advisor to the U.S. State Department’s Special Coordinator for Ebola and as a Foreign Affairs Officer at the U.S. Department of State in the Bureau of Economic and Business Affairs. 

She served on the Federal Emergency Management Agency’s (FEMA) National Advisory Council, as chair of the Equity Working Group. She serves on the Board of Directors for Project HOPE and the YMCA of Central Maryland. 

Nicolette earned Bachelor of Science degrees in Chemical Engineering and Biological Sciences from Carnegie Mellon University, a PhD in Pharmacology and Molecular Sciences from the Johns Hopkins University School of Medicine, and an MBA from the University of Baltimore.

Polly Webster is Senior Health Counsel for the U.S. Senate Finance Committee Democrats. Her portfolio includes pharmaceutical issues across Finance Committee jurisdiction health care programs, including the Committee’s work on drug prices, pharmacy benefit managers, vaccines, and drug shortages. 

Polly was previously Vice President, Federal Affairs at the Association for Accessible Medicines, which advocated on behalf of generic and biosimilar medicines. She also served as Principal Policy Advisor handling pharmacy and prescription drug policy at Kaiser Permanente. On Capitol Hill, Polly served as Congresswoman Diana DeGette’s Health Policy Director, where she spearheaded the Congresswoman’s work on the 21st Century Cures Act and other policy initiatives. She also previously held roles on the Senate Finance Committee and in Senator Jay Rockefeller’s Office (D-WV).

Polly received her Bachelors from Denison University, her Master of Public Health from The George Washington University, and her law degree from Georgetown University.

Sarah Wells Kocsis is a senior director at the Milken Institute. She oversees the Public Health programmatic pillar which focuses on mental health, prevention, chronic disease, infrastructure, and health equity, and also is responsible for day-to-day operations. In her prior role as director, Wells Kocsis led research projects on public-private partnerships in public healthy, chronic kidney disease, obesity, the pharmaceutical supply chain, and employer-sponsored health care. As a recognized thought leader on these issues, Wells Kocsis speaks externally about this work at conferences, roundtables, and with the media. For the past three decades, she has helped organizations at the nexus of science, innovation, business, and philanthropy drive public-policy solutions to optimize patient access to care. Wells Kocsis has held senior-level positions at Boston Scientific, Amgen, Hologic, and the Society for Women's Health Research. She holds a master's in business administration from the University of Virginia's Darden Graduate School of Business and a bachelor of science in biology from Tulane University.

Carrie Dunford is the Chief Pharmacy Officer and Vice President of Clinical Services at Intermountain Health. She is responsible for leading enterprise pharmacy services for acute, ambulatory, community, home delivery, and specialty pharmacy as well as pain services. Carrie earned her Bachelor of Science degree in pharmacy from the University of Utah, a Doctor of Pharmacy degree from Idaho State University and a Master of Business Administration degree from Western Governors University. Prior to her leadership roles, Carrie worked in many clinical roles as a pharmacist caring for patients in oncology, medicine, and community pharmacy and hospital. Carrie has more than 20 years of pharmacy experience with expertise in clinical pharmacy, pharmacy operations, and regulatory compliance. She is currently a pharmacist on the Utah State Board of Pharmacy and USHP Advocacy.  Carrie lives with her husband and two sons in South Jordan, Utah. In her free time, Carrie enjoys the mountains of Utah boating and snowmobiling.

Terri Lyle Wilson is the Vice President of Pharmacy at the Children’s Hospital Association (CHA), bringing extensive experience across diverse pharmacy practice settings, including home infusion and hospice, ambulatory care, population health, and supporting the nation’s leading pediatric hospitals and the patients they serve.

Terri leads collaborative efforts among children’s hospitals and health systems to enhance patient care, hospital sustainability, and healthcare delivery through pharmacy strategy, drug shortage mitigation, group purchasing, and clinical quality initiatives. With a focus on innovation and impact, Wilson drives solutions that improve care quality, optimize hospital operations, and strengthen pharmacy services across pediatric institutions nationwide.

A respected industry leader, Terri serves on multiple boards and committees, including past Chair of the End Drug Shortages Alliance (EDSA), Board Member of the Healthcare Supply Chain Association (HSCA), and advisor to Angels for Change. Recognized for her contributions to pharmacy and healthcare advocacy, Wilson has received industry awards such as the 2025 End Drug Shortage Alliance “Catalyst Award”, the 2023 Angels for Change “Changemaker of the Year” and earned the Certified Pharmacy Executive Leader (CPEL) Certificate of Leadership.

Mark Spiecker is President of STAQ Pharma, a 503B outsourcing facility with operations in Colorado and Ohio that manufactures sterile injectable compounded medications for hospitals nationwide. Under his leadership, STAQ Pharma has been nationally recognized for helping address critical drug shortages impacting the nation’s most vulnerable patients.

Mark brings deep experience in strategy, operations, and organizational transformation, having led and advised companies through growth, turnaround, and exit. He is the former CEO of Sharklet Technologies, Inc., a medical device company whose sharkskin-inspired surface technology controls bacteria and was successfully sold to a Chinese bioscience group. Earlier in his career, Mark held senior leadership roles at Adelphia Communications and 360networks, where he played key roles in bankruptcy reorganizations and operational restructuring.

An active civic and community leader, Mark serves on multiple nonprofit and advisory boards, including the Denver Museum of Nature & Science, Food Bank of the Rockies, Ending Drug Shortages Alliance, and Angels for Change. He holds an MBA and B.S.B.A. from Rockhurst University and an A.A. from the University of Florida. Mark enjoys spending time with his five children and embracing all that Colorado has to offer.

Chan Harjivan is a strategist working at the intersection of drug pricing, supply chain resilience, and biosecurity. Drawing on experience across health systems, government, and biopharma, his work focuses on aligning incentives, data, and regulation to make medicines more affordable, available, and secure.

Chan previously led the White House–based Biopharma Coalition (Bio-5), coordinating the U.S., EU, India, Japan, and the Republic of Korea to strengthen biopharmaceutical supply chains. He also oversaw U.S. government preparedness and response to biological threats, including R&D, vaccines, diagnostics, and supply chain resilience, and was a key architect of the $18B Operation Warp Speed initiative.

He is the co-founder of SaponiQx, a next-generation vaccine adjuvant company valued at $250M on exit, whose technology supports vaccines including GSK’s Shingrix. Chan has also served as Managing Director and Partner at Boston Consulting Group and Senior Partner at PwC, advising leading pharmaceutical companies and global health organizations. He is a frequent speaker and commentator on health and biosecurity strategy.

Christine Dunn Vice President, Portfolio Strategy Supply Chain. Leads the development of a long-term strategy plan for our health system customers around inventory management and shortage prevention portfolio for at Cencora. A pharmacist by background for 20+ years in the acute care space starting as a clinical pharmacist and then working in a variety of leadership roles within health systems. Prior to her joining Cencora, she spent the last 11 years at HealthTrust Performance Group supporting HCA supply chain pharmacy operations and then transitioning to AVP Pharmacy Sourcing on their GPO team.  Her background in pharmacy contracting and hospital procurement/operations is what has led her to be very passionate about working to end drug shortages.

Healthcare Supply Chain Association (HSCA) President and CEO Angie Boliver is a group purchasing industry expert and public affairs veteran with more than 20 years of experience.

Boliver joined HSCA in 2024 from AB Communications Strategies, which she founded and led as President and Principal Consultant. Throughout her career, she has held a number of leadership positions at the forefront of public policy, law, public relations, and communications, including at a national GPO where she first served as Senior Legal Counsel and then Vice President of Strategic Communications, and Public Relations. Boliver has also worked as an attorney for Jones Day.

Boliver holds a bachelor’s degree in English literature from Hardin-Simmons University, a Master of Arts degree in English literature from Southern Methodist University, and a Juris Doctor degree from Southern Methodist’s Dedman School of Law.

Ms. Arlene Joyner is the Director of the Center for Industrial Base Management and Supply Chain for the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). In this role, she is responsible for leading HHS efforts on Advanced Manufacturing Technologies, Personal Protective Equipment, Testing and Diagnostics, and Supply Chain Optimization. 

Ms. Joyner’s previous roles within ASPR include Deputy Director for the Pharmaceutical Countermeasures Infrastructure Division and Branch Chief for the Pharmaceutical Countermeasure Infrastructure (PCI) Department within the Center for the Biomedical Advanced Research and Development Authority (BARDA) where she started her federal service 11 years ago in 2011. Prior to joining ASPR, Ms. Joyner worked for six years at Merck and Company in Quality Auditing and Vaccine Manufacturing Operations, and 16 years at Baxter Vaccines Division as a Manufacturing Manager, Materials Management and Supply Chain Manager, and Manufacturing Operations Director.

Ms. Joyner holds a Bachelors degree in Chemical Engineering from Penn State University and a Master of Science in Chemical Engineering from Villanova University

James Coburn joined ARPA-H as a Portfolio Lead in July 2025 on detail from his position as Senior Advisor for Emerging Technologies in the Food and Drug Administration’s Office of the Chief Scientist. There, he led a team that increases the agency’s experience with cross-cutting advanced manufacturing technologies. His expertise is medical manufacturing advancements, accelerated adoption of those emerging technologies, and supply chain resilience. Coburn regularly coordinates with industry and government groups on medical supply chain resilience and was previously the Medical Manufacturing Innovation Lead for the White House Office of Science and Technology Policy.   

In his role in the Public Health Service, Coburn has deployed to disasters and outbreak zones where he has seen agile processes and digital systems help to improve the response. He received his master’s degree in mechanical engineering from Brown University and is a recognized expert in additive manufacturing for medical products.

Dr. Eric S. Edwards is currently the co-founder and CEO of Phlow Corporation, a certified B-Corporation focused on reshoring critical essential medicines and their ingredients in America leveraging advanced development and manufacturing technologies. Previously, Dr. Edwards was an independent executive healthcare, pharmaceutical, and medical device consultant to small and large multi-national corporations. Prior to consulting, Dr. Edwards was the co-founder of Kaléo, Inc., a pharmaceutical company in Richmond, VA developing novel medicines for the treatment of a variety of chronic and acute-care diseases. He is co-inventor of several currently marketed products, including AUVI-Q, an epinephrine Auto-injector for the treatment of allergic emergencies (anaphylaxis) as well as the Naloxone Auto-injector (Rapid Opioid Countermeasure System) currently being deployed by the DoD in case of an opioid-related attack on the homeland or abroad as a part of the warfighter’s medical arsenal. His inventions have produced cumulative sales of over $1 Billion.

Dr. Edwards has over 240 patents and has authored numerous publications in the allergy and opioid use disorder arena as well as on America’s essential medicine supply chain. Dr. Edwards has been active on several committees and boards, including being appointed by the Governor to the Board of the Virginia Biotechnology Research Park Authority/ Activation Capital and serving as a mentor and Board member for Lighthouse Labs, a nationally-recognized, Top 25 Accelerator. He is also on the founding Board of the Food Allergy Science Initiative (FASI) working with world-class researchers to find a cure and develop treatments for food allergies. Dr. Edwards graduated from Virginia Commonwealth University’s guaranteed admission program. While at VCU/MCV, he received a B.S. in Biology, his Ph.D. in the Pharmaceutical Sciences, and M.D. degrees.

Lindsey Thomas is Senior Vice President of Marketing at Fresenius Kabi USA, a leading manufacturer of sterile injectable medications.  She is responsible for all aspects of Marketing and Product Management strategy, execution and analytics for the U.S. Pharmaceuticals business.  Lindsey joined Fresenius Kabi in 2013 and has held multiple Marketing and Sales leadership roles.  

Lindsey has nearly 25 years of experience in the pharmaceutical industry and a track record of delivering product and award-winning labeling solutions that optimize pharmacy workflow while advancing medication safety best practices.  Lindsey has launched more than 125 products over the course of her career.  

Lindsey has been recognized for her authentic leadership style and focus on empathy and collaboration to achieve win-win outcomes.  She is active in industry efforts to find a solution to drug shortages and was named Changemaker of the Year in 2024 by Patient Advocacy Non-profit, Angels for Change.  She has sat on the boards of the End Drug Shortages Alliance and the American Society of Health-System Pharmacists Foundation.

Prior to her time at Fresenius Kabi, Lindsey held commercial leadership roles at Sagent Pharmaceuticals and Baxter Healthcare.  

Lindsey holds a B.S. in Marketing, International Business and Spanish from Marquette University and an MBA from Northwestern’s Kellogg School of Management. 

Marta E. Wosińska, Ph.D. is a Senior Fellow in Economic Studies at The Brookings Institution.  She is a healthcare economist specializing in prescription drug markets and a leading expert on the economics of drug shortages.  She has experience spanning top academic institutions, prominent think tanks, and federal agencies including FTC, FDA, and HHS Office of Inspector General.